Grifols (NASDAQ:GRFS) Shares Gap Up - Here's Why

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $8.34, but opened at $8.73. Grifols shares last traded at $8.67, with a volume of 139,494 shares traded.

Grifols Stock Down 1.7 %

The firm's fifty day moving average price is $8.78 and its 200-day moving average price is $7.75. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. The firm has a market capitalization of $5.64 billion, a P/E ratio of 8.20 and a beta of 0.50.

Grifols (NASDAQ:GRFS - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. As a group, equities research analysts forecast that Grifols, S.A. will post 0.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in shares of Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 1,135 shares in the last quarter. NBC Securities Inc. boosted its holdings in shares of Grifols by 2.8% in the third quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company's stock valued at $463,000 after acquiring an additional 1,433 shares in the last quarter. Signaturefd LLC boosted its holdings in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock worth $48,000 after buying an additional 2,153 shares in the last quarter. US Bancorp DE boosted its holdings in Grifols by 12.3% during the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company's stock worth $183,000 after buying an additional 2,256 shares in the last quarter. Finally, Creative Planning boosted its holdings in Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company's stock worth $154,000 after buying an additional 3,614 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.